Tough German cost watchdogs compliment Novartis' Jakavi; Pfizer rolls out supplement brand in U.K.;

@FiercePharma: Top-read on FP Weds: Don't worry about a hep C pricing war, analysts tell Gilead-watchers. Article | Follow @FiercePharma

@TracyStaton: Been on vacay? @FiercePharma's top August news so far: Pfizer faces growing legal threat over Lipitor. Story | Follow @TracyStaton

@EricPFierce: FDA warning letter for India's Marck Biosciences lays out in vivid detail why it banned it plant. More | Follow @EricPFierce

@CarlyHFierce: @US_FDA approves first needle-free flu vaccine injection system. Story | Follow @CarlyHFierce

> Germany's cost-effectiveness body decided that Novartis' ($NVS) Jakavi (ruxolitinib) provided "considerable added benefit" in patients with myelofibrosis. Report

> Pfizer's ($PFE) consumer health unit has rolled out its Emergen-C supplement in the U.K.'s Tesco supermarkets and Boots pharmacies. Report

> Novartis ($NVS) persuaded a California judge to toss out a lawsuit claiming its bone drug Zometa caused jaw injuries, for the second time. Report (reg. req.)

> Galena Biopharma ($GALE) tapped its COO, Mark Schwartz, to take the help as president and CEO, replacing Mark Ahn, who has resigned to pursue other goals, the company said. Release

> Biogen Idec ($BIIB) named Adriana Karaboutis as its EVP of technology and business solutions; she joins the biotech company from Dell, where she was CIO. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: NY Senators tell FDA to stop sales of power morcellators. Article | Follow @FierceMedDev

@VarunSaxena2: Russian scientists close in on drug-delivering nanorobots. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Chinese hackers infiltrate U.S. health care system as China's medical device industry booms. Bloomberg story | Follow @EmilyWFierce

> FDA allows Covidien to restart manufacturing of two recalled devices. Story

> FDA clarifies UDI requirements with new guidance. Story

> Baxter to invest $300M, hire 200 to expand hemodialysis manufacturing. Article

Biotech News

@FierceBiotech: Lilly joins the list of Enbrel-beaters with head-to-head psoriasis showdown. News | Follow @FierceBiotech

@JohnCFierce: Global fear of Ebola outbreak stokes a frenzy of new R&D, production plans. More | Follow @JohnCFierce

@DamianFierce: ICYMI yesterday: $FOLD CEO on positive new migalastat data, next-gen Fabry treatment and the importance of perseverance. Report | Follow @DamianFierce

@EmilyMFierce: Parents more likely to vaccinate kids against measles when child's, not society's, benefits are stressed. FierceVaccines story | Follow @EmilyMFierce

> J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test. Story

> Baxter's next hemophilia drug clocks a Phase III success. More

> GlaxoSmithKline grabs FDA approval for its latest asthma treatment. Article

Vaccines News

> Measles vaccination more likely when child's, not society's, benefits are stressed. Report

> Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020. More

> Chikungunya vaccine protects against virus in small Phase I study. Article

> FDA approves first needle-free flu vaccine injection system. More

> Clinical failure for Merck KGaA's cancer vaccine dents subpopulation hopes. Story

Pharma Manufacturing News

> Pfizer recalls nearly 94,000 vials of Depo-Medrol. Item

> Novo cutting emissions while building capacity at massive Denmark plant. Report

> Lonza gets a break on the tax break it got for the U.S. plant it is closing. More

> Hikma seizes on 'opportunities' for injectables growth. Article

> DOJ investigates Dr. Reddy's for failing to protect children with packaging. Story

And Finally... Another study found that combining therapy with drugs to treat severe depression is more effective than antidepressants alone. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.